Showing results (121-130 of 156) with videos related to

Sort By:
Pageof 16
Breast Cancer (Tokyo, Japan)|August 7, 2009
Predictive factors for anthracycline-based chemotherapy for human breast cancerYasuo Miyoshi, Masafumi Kurosumi, Junichi Kurebayashi, et al.
Breast Cancer Research and Treatment|September 21, 2016
Young adult breast cancer patients have a poor prognosis independent of prognostic clinicopathological factors: a study from the Japanese Breast Cancer RegistryAkemi Kataoka, Takayuki Iwamoto, Eriko Tokunaga, et al.
Oncotarget|October 18, 2019
Clinical significance of evaluating hormone receptor and HER2 protein using cell block against metastatic breast cancer: a multi-institutional studyAkira Matsui, Yuya Murata, Norikazu Masuda, et al.
Therapeutic Advances in Medical Oncology|April 30, 2024
TROPION-Breast03: a randomized phase III global trial of datopotamab deruxtecan ± durvalumab in patients with triple-negative breast cancer and residual invasive disease at surgical resection after neoadjuvant therapyAditya Bardia, Lajos Pusztai, Kathy Albain, et al.
The New England Journal of Medicine|October 22, 2025
Sacituzumab Govitecan in Untreated, Advanced Triple-Negative Breast CancerJavier Cortés, Kevin Punie, Carlos Barrios, et al.
Breast Cancer Research and Treatment|May 20, 2024
Long-term outcomes of neoadjuvant trastuzumab emtansine + pertuzumab (T-DM1 + P) and docetaxel + carboplatin + trastuzumab + pertuzumab (TCbHP) for HER2-positive primary breast cancer: results of the randomized phase 2 JBCRG20 study (Neo-peaks)Toshimi Takano, Norikazu Masuda, Mitsuya Ito, et al.
Cancers|August 27, 2021
Long-Term Outcomes of a Randomized Study of Neoadjuvant Induction Dual HER2 Blockade with Trastuzumab and Lapatinib Followed by Weekly Paclitaxel Plus Dual HER2 Blockade for HER2-Positive Primary Breast Cancer (Neo-Lath Study)Eriko Tokunaga, Norikazu Masuda, Naohito Yamamoto, et al.
The Annals of Pharmacotherapy|June 15, 2014
Time Course of Calcium Concentrations and Risk Factors for Hypocalcemia in Patients Receiving Denosumab for the Treatment of Bone Metastases From CancerHiroaki Ikesue, Toshikazu Tsuji, Koujiro Hata, et al.
Breast Cancer (Tokyo, Japan)|June 10, 2026
Quality-of-life assessment in the randomized JBCRG-M06/EMERALD study of eribulin plus dual HER2 blockade in HER2-positive locally advanced or metastatic breast cancerTsuguo Iwatani, Norikazu Masuda, Shigehira Saji, et al.
Breast Cancer Research and Treatment|September 23, 2021
A phase II study of sequential treatment with anthracycline and taxane followed by eribulin in patients with HER2-negative, locally advanced breast cancer (JBCRG-17)Ippei Fukada, Yoshinori Ito, Naoto Kondo, et al.
Pageof 16